Skip to content
The Nexus
DossierENTITY

Emily G. Hilliard

Coverage of Emily G. Hilliard in the Nexus archive.

Earliest in view: Jun 11 · 19:16 UTCMost recent: Jun 11 · 19:16 UTC
Co-mentioned in this coverage
Keytrudatopic1Merck & Co.organization1Kumar Prabhashperson1American Society of Clinical Oncologyorganization1U.S. Food and Drug Administrationorganization1The Cancer Calculustopic1ICIJorganization1
Recent coverage
  • HEALTHJun 11 · 19:16 UTCICIJ
    Lowering doses of cancer drugs could slash global health spending by $30B, new research shows

    Studies suggest reducing doses of cancer drugs like Keytruda could save $30 billion annually and improve patient access. Merck changed Keytruda's dosage from weight-based to fixed, but research indicates lower doses may be equally effective, while Merck disputes these findings. The U.S. Department of Health and Human Services supports de-escalating treatments if evidence confirms safety and efficacy.